Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Anti-CD19 CAR-T Cells in Relapsed or Refractory Non-Hodgkin Lymphoma
NCT04545762Phase 1Recruiting
- Start
- Sep 2020
- Primary completion
- Oct 2026
- Modality
- Gene Editing, Gene Silencing, CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label trial of anti-CD19 CAR-T cells in non-Hodgkin lymphoma (NHL), Burkitt lymphoma (BL), marginal zone lymphoma (MZL) and 1 more (2 arms). Primary endpoints: Proportion of participants with treatment-emergent adverse events at 15 months and Proportion of participants who experience a dose-limiting toxicity at 30 days. Started Sep 2020; status: recruiting.
02
Drugs
anti-CD19 CAR-T cells
03
Conditions
non-Hodgkin lymphoma (NHL)Burkitt lymphoma (BL)marginal zone lymphoma (MZL)Waldenström macroglobulinemia (WM)
Beyond the preview
Go deeper on NCT04545762.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04545762.